Kerstin Gorlich

Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias.

A. Ganser, L. Kanz, G. Heil, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Synergistic activity of IDH1 inhibitor BAY1436032 with azacitidine in IDH1 mutant acute myeloid leukemia

R. Geffers, M. Heuser, F. Thol, 2020, Haematologica.